Blinatumomab Approved in Europe for MRD+ ALL

January 22, 2019 – The European Commission has approved blinatumomab for the treatment of adult patients with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD) of at least 0.1%.The indication is specifically for patients with Philadelphia chromosome negative (Ph-), CD19-positive B-cell precursor ALL who are in first or second complete remission (CR). The approval is based on the phase II BLAST … (leggi tutto)